Without any additional ado, here is that AI platform deal detail, such as the same may be known -- from the erstwhile folks at Fierce, then:
. . .AI drug design specialist Protillion Biosciences has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion’s platform and Merck’s drug discovery expertise.
Protillion will receive an undisclosed upfront payment, with the potential to earn research, development and commercial milestones tied to the successful development of multiple therapies, according to a June 16 release.
The deal is centered around Protillion’s Prot-MaP technology, a data generation platform designed to deliver training sets for protein design AI and enable quantitative analysis of protein libraries. The platform aims to avoid the pitfalls of model overfitting and “enables the identification of optimized biologics with sophisticated therapeutic profiles. . . .
Now you know. Onward, grinning. . . .
नमस्ते
No comments:
Post a Comment